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Aims: To perform a systematic literature review of studies in peer reviewed journals on the 
epidemiology, economics, and treatment patterns of epilepsy in selected countries in emerging 
markets.
Methods: A literature search was performed using relevant search terms to identify articles 
published from 1999 to 2000 on the epidemiology, economics, and treatment patterns of epilepsy. 
Studies were identified through electronic Embase®, Cochrane©, MEDLINE®, and PubMed® 
databases. Manual review of bibliographies allowed for the detection of additional articles.
Results: Our search yielded 65 articles. These articles contained information relevant to 
epidemiology (n = 16), treatment guidelines (n = 4), treatment patterns (n = 33), unmet needs 
(n = 4), and economics (n = 8). From a patient perspective, patients with less than or equal 
to two adverse events (AEs) while taking anti-epileptic drugs (AEDs) had significantly lower 
annual costs than those having greater than or equal to three AEs, as did patients with fewer 
seizures. The overall mean annual cost for epilepsy per patient ranged from US$773 in China 
to US$2646 in Mexico. Prevalence data varied widely and were found for countries including 
Arab League Members, China, India, and Taiwan. In Turkey, active prevalence rates ranged from 
0.08/1000 to 8.5/1000, and in Arab countries, active prevalence ranged from 0.9/1000 in Sudan 
to 6.5/1000 in Saudi Arabia. Seventeen different AEDs were used in the identified studies. The 
most common AEDs utilized were phenobarbital (21.7%), valproate (17.5%), and tiagabine 
(16.4%). In all studies, the use of AEDs resulted in an increase of patients who became seizure 
free and a reduction in seizure frequency and severity.
Conclusion: Few studies have examined the prevalence and incidence of epilepsy in emerging 
markets and study limitations tend to underestimate these rates at all times. More cost-
effectiveness, cost-minimization, and cost-benefit analyses must be performed to enhance the 
data on the economics of epilepsy and its therapy in regions with insufficient resources and 
those emerging markets which contain the majority of the world’s population. And finally, the 
study found that generic AEDs are frequently used to successfully treat patients with epilepsy 
in emerging markets.
Keywords: emerging markets, epilepsy, seizures, epidemiology, treatment patterns, guidelines, 
economics
Introduction
Epilepsy is recognized as a collection of heterogeneous syndromes characterized by 
additional conditions that coexist with seizures and impacts over 50 million people 
worldwide.1 Cognitive, emotional, and behavioral comorbidities are common.
Seizures are typically divided into two main categories: partial (focal) and 
  generalized. Generalized seizures affect both cerebral hemispheres from the onset of Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the seizure. Seizures produce loss of consciousness, either for 
long periods of time or temporarily, and are sub-categorized 
into generalized tonic-clonic, myoclonic, absence, or atonic 
subtypes.2 Partial seizures affect an area within one cerebral 
hemisphere of the brain and are the most recurring type 
of seizure experienced by patients with epilepsy.3 Partial 
seizures are further subdivided into simple partial seizures, 
where consciousness is retained; and complex partial 
  seizures, where consciousness is diminished or lost.3
In the treatment of epilepsy, no one anti-epileptic drug 
(AED) has been shown to be the most effective, and all AEDs 
have published side effects. AEDs are selected following 
consideration of side effects, ease of use, cost, and physician 
knowledge. Patients with newly diagnosed epilepsy who 
require treatment can be started on standard, first-line AEDs 
such as carbamazepine, phenytoin, valproic acid, or pheno-
barbital. Alternatively, newer AEDs introduced in the past 
decade may be used. These include gabapentin, lamotrigine, 
oxcarbazepine, or topiramate.4 Between 70% and 80% of 
individuals are successfully treated with one of the AEDs now 
available and success rates primarily depend on the etiology 
of the seizure disorder.4 However, the remaining 20%–30% 
of patients have either intractable or uncontrolled seizures or 
suffer significant adverse side effects to medication.4 As with 
the selection of first-line therapy, choosing the appropriate 
drug for the treatment of refractory epilepsy must be based 
on the appreciation of each drug’s characteristics and risks 
for each individual patient.
An emerging market economy is defined as an economy 
with low-to-middle per capita income.5 Such countries 
constitute approximately 80% of the global population, 
are often rapidly-growing and represent about 20% of the 
world’s economies.5 Although the term emerging market is 
loosely defined, countries that fall into this category, range 
from big to small, and are often considered emerging because 
of development and reform programs that have been put 
in place to launch their markets globally.5 Consequently, 
although China is considered one of the world’s foremost 
economic leaders, it is grouped into the emerging market 
category together with much smaller economies with fewer 
resources, such as Sudan or Bulgaria.
Epilepsy is common in patients admitted to hospitals in 
emerging markets.6 However, there are reported differences 
in the epidemiology, economic burden, and outcome of 
epilepsy in these regions compared to high-income countries; 
although few data from the former regions exist.6 Applying 
the International League Against Epilepsy definition of 
epilepsy is problematic in these areas, as patients often arrive 
at health facilities without adequate documentation of the 
seizure duration.7
The goal of treatment for patients with epilepsy is no 
seizures with little to no side effects. However, due to 
variabilities in clinical presentation and available resources, 
treatments are highly individualized and vary widely. 
The objective of this study is to systematically review the 
literature on epilepsy to identify incidence and prevalence 
rates, economic data, unmet needs, and treatment patterns 
in those emerging markets which contain the majority of the 
world’s population.
Methods
To ensure an extensive examination of the literature, this 
study included all published randomized clinical trials 
and observational peer-reviewed studies that examined 
factors associated with epilepsy in emerging markets.   
A comprehensive search of the literature was performed 
using PubMed, EMBASE, and Cochrane Review   databases 
on the following topics concerning epilepsy in   emerging 
markets: epidemiology, including prevalence and incidence; 
economics, including burden of disease, effects on 
productivity, and other economic issues; guidelines for 
treatment; treatment patterns; drug usage patterns; and 
unmet needs.
Search strategy and study selection
The initial search strategy was developed in the PubMed/
MEDLINE database (Table 1). A search string was 
  constructed utilizing varied approaches to identify the most 
comprehensive and effective method for retrieving studies 
specific to the study objective. Methods were explored 
using MeSH, (PubMed/MEDLINE’s controlled vocabulary 
indexing hierarchy), as well as a detailed examination of key 
terminology that would afford the best retrieval.   Provisions 
were made to include varied constructs of search terms 
with the use of the asterisk as a truncation tool (Example: 
epidemiolog* to ensure retrieval of epidemiological, 
epidemiology, etc.) Additional constraints were also placed 
upon the final search strategy to limit the retrieval to English, 
humans, and studies published in the past 10 years at the time 
of the search (between 1999 and 2010).
Following completion of the PubMed/MEDLINE 
search on January 4, 2011, the EMBASE and Cochrane 
databases were searched with comparable search strings 
on January 14, 2011 and January 18, 2011 respectively; 
duplicate citations, if present, were identified and removed. 
Figure 1 illustrates the various steps in the study selection Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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process via a flow diagram. All citations were initially 
screened for relevancy and included where appropriate. 
Each abstract and, if needed, full-text article was reviewed 
for eligibility prior to inclusion in the current analysis. 
Reference lists of relevant studies identified by searching 
the three databases (PubMed/MEDLINE, EMBASE, and 
Cochrane) were further searched manually to identify any 
additional publications of interest. Articles were excluded 
if they did not focus on epilepsy, if they did not provide 
information about the outcomes of interest, if the sample 
size was ,50, or if they pertained to infantile or pediatric 
populations ,12 years old. Articles were excluded from 
this review if the articles were not published in English or 
if the subjects studied were not humans. Reviews, letters/
comments, and case studies were also excluded from the 
review, but associated primary references were examined 
to verify they were identified by our search strategy. After 
abstracts were screened, full texts of the selected articles 
were reviewed to ensure relevance and presence of desired 
information.
Data abstraction
A structured abstraction table consisting of descriptive 
characteristics of the studies such as study objective/
hypothesis; data collection methods (study design and 
analytics); study population characteristics (sample size, 
subject inclusion and exclusion criteria); treatments; out-
comes; and limitations was used to extract the data from 
all relevant articles.
Table 1 Prevalence of epilepsy in emerging markets
Region Age group Time period Prevalence/1000  
inhabitants
Citation
Lifetime Active
Saudi Arabia Adults and children 1989 NR 6.54 Al Rajeh et al11
Members of the Arab League  
(Mauritania, Morocco, Algeria,  
Tunisia, Libya, egypt, Sudan, Djibouti,  
Comoros, Somalia, eritrea, Lebanon,  
Jordan, Syria, iraq, Saudi Arabia,  
Qatar, Kuwait, United Arab emirates,  
Oman, Bahrain, and Yemen) and  
The Palestine territory (Gaza strip  
and west Bank)
Adults and children 1950–2008 Libya 
2.3 
Tunisia 
4.0 
Saudi Arabia 
6.5 
Sudan 
0.9–2.1
NR Benamer and Grosset12
Argentina Children 1991 3.2 2.6 Somoza et al8
Argentina Adults and children 1991 6.2 3.8 Melcon et al9
Argentina Children 1994 71.9 64.8 Somoza et al10
China/Hong Kong Children 1997 NR 1.52 Kwong et al13
China/Hong Kong Adults 2002 NR 1.54 Fong et al14
China/Hong Kong Adults and children 1982–2002 NR 4.5 Hui et al15
Colombia Adults and children 1995–1996 11.3 10.1 velez and eslava-Cobos17
india Children 1991 NR 2.33 Shah et al18
Russia Adults and children 2003–2008 NR 3.4 Halász et al19
Taiwan Adults 2001 3.14 2.77 Chen et al16
Turkey Adults and children 1999–2000 0.08 NR Onal et al20
Turkey Children 1996 0.08 NR Serdarog ˇlu et al21
Turkey Adults and children 2004–2005 12.2 8.5 Calisir et al22
Turkey Adults and children 2000 6.0 5.0 velioglu et al23
Abbreviation: NR, not reported.
Citations excluded (not relevant)
(n = 474)
Articles excluded
(n = 52)
Database search
PubMed/MEDLINE
(n = 497)
EMBASE
(n = 48)
Cochrane
(n = 46)
Unique abstracts/titles screened
(n = 591)
Potentially relevant articles retrieved for
more detailed evaluation
(n = 117)
Relevant articles
(n = 65)
Figure 1 Literature review flow diagram.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Results
Our comprehensive search yielded a total of 65 articles 
(Figure 1). There were 16 articles found to have information 
relevant to epidemiology, four treatment guidelines, 
33 articles which discussed treatment patterns, four articles 
discussing unmet needs, and eight economic articles. No 
articles were found addressing the topic of drug usage trends. 
Since many of the studies included in this review evaluated 
multiple topics, there was overlap between the categories. 
Therefore, many of the articles summarized below have 
been cross-categorized and, when totaled, the numbers 
of articles cited in each category add up to more than the 
65 indicated.
epidemiology of epilepsy
Prevalence
Studies were found describing the prevalence in   Algeria, 
  Argentina, Bahrain, China, Colombia, Comoros, Djibouti, Egypt, 
Eritrea, Gaza strip, India, Iraq, Jordan,   Lebanon, Kuwait, 
Libya, Mauritania, Morocco, Oman, Qatar, Russia, Saudi 
Arabia, Somalia, Sudan, Syria, Taiwan, Tunisia, Turkey, 
United Arab Emirates, West Bank, and Yemen. These data are 
summarized in Table 1. Studies may provide data for lifetime 
prevalence, which approximate cumulative incidence, and/or 
active prevalence, which measures current seizures or current 
use of anti-epileptic drugs.
In the literature identified for this review, the   prevalence 
of epilepsy in emerging markets varied according to 
the population studied. For example, three studies dis-
cussed the prevalence of epilepsy in Argentina. In the 
primary school children population, the lifetime and 
active prevalence rates were determined to be 3.2/1000 
and 2.6/1000, respectively in one report, while lifetime 
and active prevalence was estimated to be 6.2/1000 and 
3.8/1000 in another.8,9 Another examination found a life-
time prevalence of 71.9/1000 and an active prevalence 
of 64.8/1000 in the special schools of Buenos Aires 
that   contain student populations with physical or mental 
disorders and learning problems.10
The prevalence rate for active epilepsy in Saudi Arabia 
was reported in two separate studies. In the first, prevalence 
was found to be 6.54/1000 inhabitants.11 A second study 
reported prevalence rates for several Arab countries. In 
this study, epilepsy prevalence ranged between 0.9/1000 in 
Sudan and 6.5/1000 in Saudi Arabia, reporting a median of 
2.3/1000 inhabitants.12
Three studies addressed the epidemiology of epilepsy 
in China. The prevalence of active epilepsy in China 
was estimated to be 1.52/1000 in one study and 1.54 per 
1000 inhabitants in another.13,14 Hui and Kwan estimated 
that approximately 4.5/1000 individuals in Hong Kong have 
active epilepsy.15 The lifetime and active prevalence rates of 
adult patients with epilepsy in Taiwan was estimated to be 
3.14/1000 and 2.77/1000, respectively.16
In Colombia, the general prevalence of epilepsy was 
determined to be 11.3/1000.17 In India, they found that the 
age-specific prevalence of epilepsy in school-going children 
was 3.44/1000 for those aged 11–14 years and 2.33/1000 
for those age 15–18 years.18 In the Russian Federation, 
an age-adjusted prevalence of epilepsy of 3.40/1000 was 
reported.19
Four studies examined the prevalence of epilepsy in 
Turkey with active rates ranging from 0.8/1000 to 8.5/1000 
and lifetime rates from 5/1000 to 12.2/1000. Two separate 
studies found the active prevalence rate to be 0.08/1000, while 
in Bursa a prevalence rate for active epilepsy was 8.5/1000, 
and lifetime prevalence was reported to be 12.2/1000.20–22 
Lastly, a lifetime prevalence of 6/1000 and an active epilepsy 
prevalence of 5/1000 was also reported.23
incidence
Only one study was identified that studied the incidence of 
epilepsy in emerging markets and it reported an annual inci-
dence of 174 per 100,000 persons in Qatar in 2001.12
economics of epilepsy
Articles from Bulgaria, China, India, Korea and Mexico were 
identified. These data are summarized in Tables 2 and 3.
Table 2 Societal perspective – economic data
Year Country Patient population Costs of epilepsy Cost burden Reference
2008 China Adults and children ↓103¥ (16 USD) Shanghai-mean costs of health care contact with town doctors Ding et al28
↓12¥ (2 USD) Ningxia-health care costs to town doctors
↑10¥ (1.5 USD) Ningxia-time costs to town doctors
2009 China Adults and children 1968¥ (289 USD) Loss of productivity Hong et al24
2001 india Adults 147 rupees (3 USD) Drug monitoring service to hospital Rane et al25
22 rupees (0.50 USD) Drug monitoring service to hospital per seizure prevented
Abbreviations: ¥, Chinese yuan, renminbi; USD, United States dollar; ↑, increased; ↓, decreased.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Societal perspective
From a societal perspective, costs due to loss of productivity 
averaged US$289 per patient per year in China (Table 2).24 
In India, the direct costs were calculated to be 147 rupees 
(US$3.26) to hospitals per epileptic patient, while the cost 
of monitoring therapeutic drugs to the hospital, per seizure 
prevented, was 22.35 rupees (US$0.50).25
Payer perspective
In Korea, from the payer’s perspective, adjunctive therapy led 
to the incremental cost-effectiveness ratios being estimated at 
US$44 per seizure-free day per adult patient and US$11,084 
per quality-adjusted life years gained.26
Patient perspective
From a patient perspective, Bulgarian patients with one or 
two adverse events (AEs) had significantly lower annual 
costs (mean €338.73) than those with more than two AEs 
(mean €806.03) while taking AED monotherapy (Table 3). 
Monotherapy patients with fewer seizures also showed 
significantly lower costs (mean €85.97), compared with 
patients with more frequent seizures (mean €810.43). 
Patients on AED therapy, with 50% or more seizure reduction 
compared with baseline, showed significantly lower costs 
(mean 402.67€) than those with worse control (mean 
€931.30).27
In rural Shanghai and Ningxia, China, the total 1-year 
expenses per patient before AED treatment were 1494.30¥ 
(US$229) and 213.09¥ (US$33), respectively, and these 
expenses decreased to 91.52¥ (US$14) and 45.90¥ (US$7), 
respectively (P , 0.05) following treatment for 1 year.28 
In another study from China, direct medical care costs 
were 2529¥ (US$372) per year per patient, of which anti-
epileptic drugs (1651¥ or US$243) accounted for the major 
cost component.24 Nonmedical direct costs were much less 
than direct health care costs, averaging approximately 756¥ 
(US$111). The overall mean annual cost for epilepsy per 
patient in this series was approximately 5253¥ (US$773), 
and these costs accounted for more than half of the mean 
annual income.24
In India, direct costs were calculated, including cost to 
the hospital of providing the therapeutic drug monitoring 
(TDM) service, cost to the hospital per seizure prevented, 
and cost to the patient per seizure prevented.25 The cost per 
patient of the TDM service to the hospital was 147 rupees 
(US$3.26), while each patient was charged only 30 rupees 
Table 3 Patient perspective – economic data
Year Country Patient population Outcome measure Mean cost (USD) Reference
2008 Bulgaria Adults #2 Aes 339€ ($487) Balabanov et al27
$2 Aes 806€ ($1158)
CBZ patients .26 weeks between seizures 386€ ($555)
,26 weeks between seizures 810€ ($1164)
CBZ $ 50% seizure reduction 403€ ($579)
CBZ # 50% seizure reduction 931€ ($1338)
2008 China Adults and children Shanghai: 1-year expenses per  
PB treated patient
1494¥ decreased to 92¥  
at 1 year ($234 to $14)
Ding et al28
Ningxia: 1-year expenses per  
PB treated patient
213¥ decreased to 46¥  
at 1 year ($33 to $7)
2009 China Adults and children Direct medical care costs 2529¥ ($395) Hong et al24
Antiepileptic drugs 1651¥ ($258)
Non-medical direct costs 756¥ ($118)
Annual cost for epilepsy/patient 5253¥ ($821)
2001 india Adults TDM cost per patient 147  ($114) Rane et al25
TDM cost patient charged 30  ($0.65)
TDM cost to hospital per seizure prevented 22  ($0.48)
TDM cost to patient per seizure prevented 5  ($0.10)
2005 india Adults Cost of drug at entry – monotherapy 2276  ($49) Thomas et al29
Cost of drug at entry – polytherapy 3629  ($79)
Cost of drug at last follow-up – monotherapy 1898  ($41)
Cost of drug at last follow-up – polytherapy 4929  ($107)
2006 Mexico Adults and children Annual healthcare cost per patient 2646 USD Garcia- 
Contreras et al30
Note: USD conversion rates as at August 21, 2011.
Abbreviations: ¥, Chinese yuan, renminbi; USD, United States dollar; €, euro; PB, phenobarbital; TDM, therapeutic drug monitoring.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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(US$0.67) per sample, reflecting the cost of the consumables 
only. The cost of TDM to the hospital per seizure prevented 
was 22.35 rupees (US$0.50) while the cost to the patient 
was 4.50 rupees (US$0.10). A second study found that the 
cost of drug therapy for patients at entry ranged from 2276 
rupees (US$50.46) to 3629 rupees (US$80.46). At the time 
of last follow-up, it ranged from 1898 rupees (US$42.08) to 
4929 rupees (US$109.28).29
Lastly, in Mexico, the annual mean health care cost per 
treated patient was found to be US$2646. Ambulatory health 
care contributed to 76% of the total, and hospital health care 
contributed 24%.30
Treatment guidelines
The goal of epilepsy treatment is to maintain a normal 
lifestyle, ideally, by complete seizure control with minimal 
side effects. For the majority of patients with epilepsy, AED 
therapy is used. The quality of care and therapeutic outcome 
may differ across countries because of numerous variations 
in medical systems. Few additional studies were identified 
that addressed ways by which care providers could more 
effectively identify patients with epilepsy or determine an 
appropriate therapy.
In China, age-varying differences between the effective-
ness of carbamazepine and valproate for the treatment of 
generalized onset and partial onset seizures were reported 
in a study that suggested valproate may be more effective at 
treating epilepsy in younger patients, while carbamazepine 
may be more effective at treating patients older than 30.31 
An electroencephalography screening process by which 
high-risk patients can be better screened was described 
as well as a method used to aid health care providers in 
the identification of patients with generalized tonic-clonic 
seizures.32,33
Treatment patterns
In the articles identified, data on the treatment patterns of 
12,317 patients with generalized or partial onset epilepsy 
were found for countries including Argentina, Brazil, China, 
Czech Republic, India, Korea, Poland, Russia, and Taiwan. 
These data are summarized in Table 4. Seventeen different 
AEDs were used in these studies. The proportion of patients 
receiving each AED was phenobarbital (21.7%), valproate 
(17.5%), tiagabine (16.4%), oxcarbazepine (8.3%), leveti-
racetam (8.1%), topiramate (7.2%), eslicarbazepine acetate 
(5.8%), lacosamide (3.9%), lamotrigine (2.1%), pregabalin 
(1.9%), and clobazam (1.6%). Zonisamide, primidone, 
clonazepam, phenytoin, gabapentin, and carbamazepine 
were used in ,1% of the population each. In all studies, the 
use of these AEDs resulted in an increase of patients who 
became seizure free and a reduction of seizure frequency 
and severity.
Unmet needs
The literature review identified five articles discussing 
the unmet needs of patients with epilepsy in emerging 
markets. There were two studies of the Indian population 
and one study found for each of the countries of Bahrain, 
the Czech Republic, and Kuwait. In general, the articles 
identified the need for developing treatment strategies, 
counseling therapies, and social support for people with 
epilepsy to improve their quality of life.34,35 As the mean 
delay in diagnosis is 1.5 ± 4 years in parts of India, facilities 
for epilepsy surgery, therapeutic drug monitoring, and 
services of clinical psychologist or medical social workers 
are also needed.36 In Kuwait, objections to shaking hands 
with, working with, marrying, and employing patients 
with epilepsy were reported by 16.0%, 24.8%, 71.6%, and 
45.2%, of the general population, respectively.37 Therefore, 
continuing effective educational interventions are needed 
to improve the understanding of epilepsy and to diminish 
social discrimination and misconceptions against these 
patients.37
Discussion
This review is a thorough study of epilepsy in emerging 
markets summarizing the available literature on epidemi-
ology, economics, unmet needs, treatment and drug usage 
patterns, and guidelines for the treatment of epilepsy in 
emerging markets. To more fully grasp the information 
found in this review concerning epilepsy and its treatment 
in emerging markets, it is useful to compare these findings 
to data from developed countries with higher per capita 
incomes.
Because it is often less complicated to obtain information 
regarding prevalence than incidence, many more prevalence 
studies of epilepsy from diverse populations were found. 
In general, prevalence rates per 1000 individuals varied 
widely in this review. In Argentina and China, rates ranged 
from 2.6–3.8 and 1.5–4.5 respectively.8,9,13,15 In India, 
prevalence was reported to be 2.3 and in Turkey, rates ranged 
from 0.08 to 8.5 individuals.18,20,22 Studies from Argentina 
reported a wide range of per 1000 population rates of 3.2, 
6.2, and 71.9 in the general school, general, and the special 
school populations, respectively. The prevalence study 
from southern Sudan was based on a population estimate Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 4 Clinical trials of therapies for epilepsy
Country Therapeutic  
agent(s)
Patient  
population
Trial design Key findings Reference
Brazil Clobazam Partial onset  
patients with  
refractory epilepsy
Retrospective Following treatment, 7% of patients were 
seizure free, 49% had $50% of improvement 
in seizure control, 40% had ,50% of 
improvement in seizure control.
Montenegro  
et al50
Brazil Clobazam as  
add-on agent
Generalized Retrospective Following treatment, 20% of patients were 
seizure-free, 25% had more than 75% 
improvement in seizure control,  
10% had more than 50% and 26%  
were non responders to treatment.
Montenegro  
et al51
China Phenobarbital Generalized Prospective  
observational
Following treatment, 78% of the patients  
had a 50% or greater reduction in seizure  
frequency and 43% were seizure free.
Liu et al52
China Topiramate 
monotherapy vs  
add-on agent
Generalized and  
Partial onset
Prospective  
observational
The rate of AEs was significantly higher  
with use of topiramate as monotherapy  
than as adjunctive therapy.
Lu et al53
China Zonisamide as  
add-on agent
Partial onset  
refractory epilepsy
RCT Zonisamide showed significantly greater  
efficacy compared with placebo.
Lu et al54
China Topiramate 
monotherapy vs  
add-on agent
Generalized Retrospective The percentage of seizure-free patients was 
69% in the topiramate monotherapy group 
and 42% in the topiramate add-on group.
Lu et al55
China valproate and  
Primidone
Partial onset  
patients unresponsive  
to carbamazepine
Prospective  
observational
Significantly more patients on Valproate  
(51%) achieved a greater than 50% seizure 
reduction than on Primidone (34%).
Sun et al56
China Levetiracetam as  
add-on agent
Partial onset RCT Levetiracetam significantly decreased  
weekly partial-onset seizure frequency  
over placebo by 27%.
wu et al57
China Levetiracetam as  
add-on agent
Partial onset RCT The proportion of patients with a  
minimum of 50% reduction in partial  
seizure frequency occurred in 46% of the 
treatment group, compared with 39%  
of the placebo group.
Xiao et al58
Czech Republic Levetiracetam Generalized and  
partial onset
Retrospective A significant decrease in the number 
of seizures occurred after 6 months of 
treatment.
Tlusta et al35
india Phenobarbital  
Carbamazepine  
Phenytoin  
valproate  
Clobazam  
Clonazepam  
Lamotrigine 
Oxcarbazepine
Generalized and  
partial onset  
elderly population
Retrospective One year remission rate was 56%. Tran et al59
india Phenobarbital  
or phenytoin
Generalized and  
partial onset
Prospective  
observational
The proportion with remission at each of  
four successive years of follow-up ranged  
from 58% to 66% for patients who were  
drug compliant and who had a lifetime  
total of 30 or fewer generalized tonic- 
clonic seizures.
Mani et al49
india Gabapentin  
or Lamotrigine
Partial onset  
patients refractory  
to carbamazepine
RCT The average frequency of partial seizures 
decreased significantly in both groups. 
The responder rate was 78% and 92% for 
gabapentin and lamotrigine respectively.
Sethi et al60
Multiple Lacosamide Partial onset RCT The median percent reduction in seizure 
frequency was 21% for placebo, 35%  
for lacosamide 200 mg/day, and 36% for  
400 mg/day.
Halász et al61
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Table 4 (Continued)
Country Therapeutic  
agent(s)
Patient  
population
Trial design Key findings Reference
Multiple eslicarbazepine  
acetate
Partial onset  
patients refractory  
to treatment with  
one or two  
concomitant AeDs
RCT Seizure frequency was significantly lower  
in the treatment groups as compared  
to placebo.
elger et al62
Multiple eslicarbazepine  
acetate
Partial onset Prospective  
observational
Seizure frequency decreased by 39%  
during the first 4 weeks and between  
48% and 56% thereafter.
Halász et al19
Multiple valproate Generalized and  
partial onset
Prospective  
observational
At 6 months, 77% of subjects were 
seizure free.
Jedrzejczak 
et al63
Multiple valproate Partial onset Prospective  
observational
At 6 months, 87% of patients became  
seizure free.
Deleu et al64
Multiple Levetiracetam  
as add-on agent
Partial onset Prospective  
observational
44% of patients had a $50% reduction in 
seizure frequency, with a median reduction 
of 46%. 18% became seizure free during 
treatment.
Kwan et al65
Multiple Oxcarbazepine Partial onset RCT The median reduction in seizure frequency 
was 26%, 40%, 50%, or 8% for patients 
receiving 600, 1200, or 2400 mg/d  
treatment or placebo, respectively.  
Of patients in the 600, 1200, or 2400 mg/d 
treatment groups, 27%, 42%, and 50% 
respectively, had more than 50% reduction  
in seizure frequency compared  
with 13% for placebo.
Barcs et al66
Poland Tiagabine as  
add-on agent
Generalized and  
partial onset
Prospective  
observational
The mean initial seizure rate per patient 
decreased following treatment.  
The percent of responders with $50% 
reduction of seizure rate reached 52%  
after 8 weeks and 77% after 16 weeks.
Chmielewska 
and Stelmasiak67
Poland Tiagabine as  
add-on agent
Generalized and  
partial onset
Prospective  
observational
71% patients had a $50% decrease in  
seizure frequency compared with baseline. 
The beneficial effect of treatment on  
seizure reduction was most marked in  
patients with partial seizures.
Jedrzejczak68
Poland Topiramate as  
add-on agent with 
Carbamazepine
Partial onset Retrospective Most Aes with adjunctive therapy  
were transient.
Majkowski  
et al69
Poland Lamotrigine vs  
valproate
Generalized Retrospective Valproate showed comparable efficacy  
in all syndromes where lamotrigine  
showed better efficacy in childhood  
epilepsy.
Mazurkiewicz-
Beldzinska  
et al70
Russia Pregabalin as  
add-on agent
Partial onset Prospective  
observational
The patients receiving treatment showed  
a significant reduction at the end of the  
first month in the number of seizures.
Bondarenko ii71
Russia Oxcarbazepine 
monotherapy  
and as add-on agent
Generalized and  
partial onset
Non  
randomized  
clinical trial
52% of patients had 50% less seizures;  
35% of patients had a reduced number of  
seizures by 75%; 18% of patients had full 
control. in patients who never received  
AeD therapy, full treatment control was 
achieved in 74% and among patients who  
had received AeD treatment full control  
was reached in 44%. Monotherapy or 
combined therapy also led to  
decreased seizure duration.
Burd et al72
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Table 4 (Continued)
Country Therapeutic  
agent(s)
Patient  
population
Trial design Key findings Reference
Russia Topiramate  
anticonvulsant  
monotherapy
Generalized and  
partial onset
Prospective  
observational
9.2% of patients had an increase in and 
duration of remission. Patients treated  
with other drug therapy had much lower  
rates of remission (4.6% for carbamazepine; 
3.0% valproate; 1.5% phenobarbital). 
Depression and anxiety developed twice  
as frequently in women than men.
Zheleznova  
et al73
South Korea Topiramate as  
add-on therapy
Partial onset  
refractory
Retrospective The median seizure frequency reduction 
rate was 69% in the treatment population. 
Cumulative seizure-free rate was 30% and  
the 1-year seizure-free rate was 13%  
at five-year follow-up.
Cho et al74
South Korea Levetiracetam Partial onset  
refractory
Prospective  
observational
The median percent reduction in weekly 
seizure frequency over the treatment  
period was 43.2%. The $50% and $75% 
responder rates were 45.4% and 36.1%, 
respectively.
Heo et al75
South Korea AeD drug  
tapering
Generalized Retrospective 75% of patients achieved complete seizure 
freedom for $1 year. AeD discontinuation 
was attempted in 91% of patients with a 
successful outcome.
Kim et al76
South Korea Pregabalin as  
add-on therapy
Partial onset  
refractory
RCT There was a significant seizure reduction 
(52.7%) with pregabalin compared to  
placebo (37.7%).
Lee et al77
Taiwan Levetiracetam  
and topiramate  
as add-on agents
Partial onset Prospective  
observational
Seizure frequency and epilepsy duration  
were not significantly different between  
the two groups compared to baseline.
Huang et al78
Taiwan Levetiracetam Treatment- 
resistant  
partial onset  
patients
RCT Levetiracetam reduced weekly partial- 
seizure frequency by 24% relative to  
placebo. Significantly more levetiracetam  
than placebo patients experienced a  
response of a $50% decrease from baseline  
in weekly frequency of partial seizures.
Tsai et al79
Abbreviations: RCT, randomized controlled trial; Ae, adverse event; AeD, anti-epileptic drug.
of ‘50–100,000’ making comparisons to other countries 
impractical.12 Yet, the general prevalence of epilepsy in 
Colombia was determined to be 11.3/1000 which was 
reported to be similar to prevalence rates found in nations 
with comparable developmental status.17
In developed countries, prevalence rates for epilepsy 
have  been  reported  to  range  from  0.027–0.1  per 
1000 individuals.38,39 It is generally accepted that the 
prevalence rate in developing countries is approximately 
double that of developed countries, at approximately 
0.15/1000.40 Variation in rates, between and within 
studies, may be attributable to differences in definitions 
of epilepsy and prevalence. For example, in the study 
by Banerjee and colleagues,38 the reported age-adjusted 
prevalence was based on medical records, whereas Onal 
and colleagues, used self-reported prevalence which was 
not confirmed by medical diagnoses.20 Yet, as prevalence 
is also a measure of the interaction of additional factors 
such as death, incidence, remission of illness, population 
migration, or access to appropriate medical care, it is 
likely that numerous factors account for the differences 
found between world populations, and not just differing 
methodologies. Population screening is needed to reveal 
the true epilepsy prevalence. Until broader, countrywide 
studies are performed, epidemiological rates will tend to 
be underestimated.
Incidence rates for North America and Europe have 
been reported to range from 16–51 per 100,000 people.38,39,41 
These rates are at the lower end of global annual incidence 
estimates of 50–70 cases per 100,000.42 Only one study was 
identified in our review reporting an incidence of 174 per 
100,000 persons in Qatar.12 However, this incidence study Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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was regional, retrospective, hospital-based, and did not have 
a clear definition of epilepsy. Interpretation of the differences 
in incidence and prevalence rates will require additional 
awareness of the role of economic, cultural, and social factors 
effecting epilepsy and its care in these markets.
The primary focus of care for patients with epilepsy is the 
prevention of further seizures which may lead to additional 
morbidity or mortality.43 The goal of treatment is the main-
tenance of a normal lifestyle, ideally by complete seizure 
control without, or with, minimal side effects. If seizures are 
provoked by external factors, avoidance might be sufficient 
to prevent attacks. However, for the majority of patients, 
AED therapy is used. In addition to seizure control, patients 
with epilepsy may have psychosocial symptoms requiring 
treatment. But the quality of care and therapeutic outcome 
may differ across countries because of variations in medi-
cal systems. The Commission of European Affairs of the 
International League Against Epilepsy has defined standards 
for appropriate care,44 which have not yet been met by some 
European countries.45 As such, the situation in many develop-
ing countries is frequently less adequate. Few studies were 
identified that addressed ways by which care providers could 
more effectively identify patients with epilepsy or suggest 
an appropriate therapy, but in the studies reviewed for this 
report, the use of AEDs resulted in an increase of patients 
who had a decreased seizure burden.
In 2005, Garcia-Contreras et al reported the annual health 
care cost per treated patient in Mexico to be US$2646.30 In 
the US, this number has been reported to be in the range of 
US$2600–9400 per person.46,47 It should be noted, however, 
that these values from the year 2000 provide an outdated 
estimate of the direct costs of epilepsy, and it is reason-
able to assume that in current monetary terms this burden 
is greater. Again, the differences between regions may be 
due to multiple factors including an underestimation of the 
affected population due to limited resources or, perhaps, the 
use of less expensive generic drugs over branded products. 
In 1999, phenytoin (dilantin) had a 42% market share of 
all AED prescriptions in the US.48 The introduction of new 
AEDs over the past decade, including gabapentin, felbamate, 
lamotrigine, tiagabine, and topiramate, has increased the 
options available for adjunctive treatment when first-line 
therapy is ineffective. Many of these newer medications, 
however, often have increased tolerability and are beginning 
to replace their preceding agents as first-line therapy.48 In 
fact, in 2004, phenytoin’s US market share had dropped to 
33%.48 Yet, while the newer, branded medications are avail-
able in many emerging markets, resources are often limited 
and the inexpensive, effective generic AEDs are often used 
out of necessity. For example, Mani et al demonstrated 
  successful treatment of epilepsy in a rural area of India 
using a combination of trained physicians and health work-
ers, generic AEDs, drug compliance, health education, and 
follow-up.49 Further analyses considering cost-minimization, 
cost-effectiveness, and cost-benefit must be done in the 
future to further understand the cost of epilepsy therapy to 
resource-poor regions.
Epilepsy care in developing countries lags behind care in 
developed countries. Precise data on delivery of neurological 
services for epilepsy is vital to optimize medical services 
for patients with limited resources. This review additionally 
highlighted the need for the development of treatment 
strategies, counseling therapies, and social support services 
for people with epilepsy.34 Facilities for epilepsy surgery, 
therapeutic drug monitoring, and clinical psychologist 
or medical social worker services are also needed, as are 
educational interventions to improve the awareness of 
epilepsy misconceptions, and to end social discrimination 
against patients with epilepsy.36,37
Other limitations must be considered when evaluating 
the literature described in this review. One limitation of 
some of the literature included in this review is study 
design. Most of the evidence was derived from retrospective 
analyses of observational, uncontrolled studies. These study 
designs cannot lead to conclusions regarding causality, but 
rather provide correlative evidence. Sample sizes were 
generally large, however, the lack of statistical differences 
in certain factors found in some studies may have been 
due to an insufficient number of subjects in treatment 
groups. Additionally, selection and treatment bias towards 
individuals residing in a particular geographical region was 
inherent to some studies. Another limitation of this literature 
review was that results were limited to English. Some of 
the objectives (eg, treatment patterns, epidemiology) might 
have been explored in more detail in older literature and 
therefore would not have been captured in our search. Our 
search strategy also focused on peer-reviewed publications 
and did not capture information from abstracts, posters, 
or dissertations, which may have limited the amount of 
information assessed for this review. Lastly, all literature 
reviews are limited by publication bias with regard to the 
articles that are available.
Conclusion
This paper is an exhaustive examination of published 
literature describing many aspects of epilepsy in emerging Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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markets. Overall, the reported incidence of epilepsy is low 
in the general population and, overall, treating patients with 
epilepsy is inexpensive and decreases the use of health care 
resources.
However, the identified clinical studies generally lacked 
standardized diagnosis criteria and used ineffectual methods 
with which to grade symptoms. Standards of care and base-
line medications varied greatly between populations and 
adjunctive medications were often arbitrarily examined. 
Studies with longer follow-up periods and larger patient 
populations are needed to document the long-term 
effectiveness of several AEDs. Many of the observations 
discussed in this review need to be further confirmed in 
larger prospective trials, and, looking for specific charac-
teristics of patients responding to certain drugs may lead 
to useful guidelines for drug choice in treating epilepsy. 
Knowledge gained in these areas will enable improvement 
to the care of people with epilepsy both in emerging markets 
and elsewhere.
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